Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06297226 · ClinicalTrials.gov registry record · Phase 2

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

Recruiting
Registry status
Phase 2
Development phase
230
Enrollment target
20
Study locations

NCT06297226: Recruiting Phase 2 study of Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

NCT06297226 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 230 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06297226, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

RECRUITING
Registry status
Phase 2
Development phase
230 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • BIOLOGICAL Arlocabtagene Autoleucel

Study Locations (20)

Florida

  • Mayo Clinic in Florida - Jacksonville
  • Miami Cancer Institute at Baptist Health, Inc. - Miami
  • Moffitt Cancer Center - Tampa

California

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 214) - Los Angeles
  • UCSF Helen Diller Medical Center at Parnassus Heights - San Francisco

Georgia

  • Winship Cancer Institute of Emory University - Atlanta
  • Northside Hospital - Atlanta

Illinois

  • Northwestern Memorial Hospital - Chicago
  • University of Chicago Medical Center - Chicago

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Banner MD Anderson Cancer Center - Gilbert

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2024-03-21
Est. Completion 2032-06-30
Phase Phase 2

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

14 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06297226

The ClinicalTrials.gov registry entry for NCT06297226 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (58% lower). The listed sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Arlocabtagene Autoleucel is the first listed.

NCT06297226 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06297226 about?

NCT06297226 is a clinical study titled "Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

What is the current status of trial NCT06297226?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2024-03-21. Estimated completion is 2032-06-30.

What conditions does trial NCT06297226 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06297226?

The interventions under investigation include: Arlocabtagene Autoleucel (BIOLOGICAL).

Who is sponsoring clinical trial NCT06297226?

This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06297226 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.